SB220025
规格
| Cas Number | 165806-53-1 |
| 规格或纯度 | Moligand™, ≥95% |
| 级别 | Moligand™ |
| 纯度 | ≥95% |
| 包装 | 10mg 或 1mg 或 5mg 或 500μg |
产品信息
| 品牌 | 阿拉丁 |
| Action Type | 抑制剂 |
| Mechanism Of Action | 丝裂原活化蛋白激酶 14 抑制剂 |
| 溶解性 | Soluble in DMSO (100 mg/ml). |
| 简短描述 | 一种有效的人p38丝裂原活化蛋白激酶 |
| 英文简短描述 | a specific and potent human p38 mitogen-activated protein kinase |
| 过滤标签 | 表观遗传学,mitogen-activated protein kinase 14 Inhibitor,PKC,p38 MAPK,Src,TGF-beta/Smad,Protein Tyrosine Kinase/RTK,MAPK/ERK Pathway |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 物理形态 | 固体 |
| 描述 |
SB220025是一种有效的人p38丝裂原活化蛋白激酶。已经显示出减少由脂多糖诱导的肿瘤坏死因子的产生。已经发现SB220025在肉芽肿发展的过程中减少白介素-1β和肿瘤坏死因子-α的表达并抑制血管生成。还发现SB220025能够减少炎性细胞因子的产生，因此可能是治疗慢性增生性炎性疾病的潜在有效方法。 |
| 英文描述 |
SB220025 is a specific and potent human p38 mitogen-activated protein kinase. It has been shown to reduce the production of tumor necrosis factor induced by lipopolysaccharide. SB220025 has been found to reduce the expression of interleukin-1β and tumor necrosis factor-α and inhibit angiogenesis over the course of granuloma development. SB220025 has also been found to be capable of reducing inflammatory cytokine production, and thus could be a potential effective treatment for chronic proliferative inflammatory disease. |